NCPC(SH:600812) Xin Lang Cai Jing·2026-01-15 01:01Core Viewpoint - The procurement process for tuberculosis drugs by the Shaanxi Provincial Center for Disease Control and Prevention has been challenged due to alleged bundling of products, limiting competition among suppliers [1][2]. Group 1: Complaint Details - The complaint was filed by North China Pharmaceutical Hebei Huanuo Co., Ltd. regarding the "tuberculosis drug procurement project," claiming that the tender documents bundled two different tuberculosis drugs, effectively restricting suppliers to those who could provide both products [1][2]. - The specific drugs in question are FDC-HR (H150mg R300mg) and FDC-HRZE (H75mg R150mg Z400mg E275mg) or FDC-HRZE (H37.5mg R75mg Z200mg E137.5mg), with only two manufacturers capable of supplying the latter, thus limiting competitive pricing [1]. Group 2: Regulatory Response - The Shaanxi Provincial Finance Department conducted a formal review of the complaint, which included written examinations and inquiries with the procurement entity and the agency involved [2]. - As a result of the review, the Finance Department mandated the procurement entity to amend the procurement documents and to initiate a new procurement process in compliance with relevant regulations [2].